Table 1.
Clinical characteristics of the patients
| Variable | Training cohort (n=81) | Validation cohort (n=60) |
|---|---|---|
| Age (yr) | 47 (16–82) | 52.5 (18–84) |
| Age > 65 yr | 13 (16.0) | 10 (16.7) |
| Male sex | 57 (70.4) | 42 (70) |
| ECOG PS | ||
| 0 | 9 (11.1) | 10 (16.7) |
| 1 | 56 (61.5) | 31 (51.7) |
| 2 | 14 (17.3) | 19 (31.6) |
| 3/4 | 2 (2.5) | 0 |
| HIV infection | 2 (2.5) | 2 (3.6)a) |
| Stage | ||
| I | 10 (12.3) | 6 (10.0) |
| II | 8 (9.9) | 9 (15.0) |
| III | 1 (1.2) | 5 (8.3) |
| IV | 62 (76.5) | 40 (66.7) |
| Bulky disease | 7 (8.6) | 1 (1.7) |
| Risk group | ||
| Low | 16 (19.8) | 9 (15.0) |
| High | 65 (80.2) | 51 (85.0) |
| LDH > UNL | 55 (67.9) | 45 (75.0) |
| β2-microglobulin (mg/dL) | 2.3 (0.76–22.2) | 2.7 (1.11–22.5) |
Values are presented as median (range) or number (%). ECOG, Eastern Cooperative Oncology Group; HIV, human immunodeficiency virus; LDH, lactate dehydrogenase; PS, performance status; UNL, upper normal limit.
a)
Data of 56 patients were available.